Analytical Data
-
Gene name
Ptger2
- Application
-
Alternative Names
(PGE receptor EP2 subtype)(PGE2 receptor EP2 subtype)(Prostanoid EP2 receptor)
-
Species
Mouse
-
Source
E. coli
-
Tag
Tag Free
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q62053
-
Expression Region
324-362aa
-
Molecular Weight
4.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the Ptger2 recombinant protein is grounded in its critical role as a receptor for prostaglandin E2 (PGE2), a lipid compound involved in various physiological processes including inflammation, immune response, and tissue homeostasis. As a member of the G protein-coupled receptor (GPCR) family, Ptger2 (also known as EP2) mediates numerous biological responses upon activation by PGE2, making it a significant target for drug development in treating diseases such as cancer, cardiovascular disorders, and inflammatory conditions. Research has indicated that the signaling pathways activated by Ptger2 play a pivotal role in regulating cell proliferation, apoptosis, and immune modulation. Given the complexity and variability of PGE2 signaling in different tissues, the production of recombinant Ptger2 protein allows for in-depth studies of its structure-function relationship, signaling mechanisms, and potential therapeutic applications. By employing recombinant DNA technology, scientists can generate large quantities of this receptor, enabling high-throughput screening of compounds that may selectively modulate its activity. Furthermore, characterizing the Ptger2 recombinant protein can provide insights into its interaction with other molecular partners and pathways, paving the way for novel strategies in drug design aimed at harnessing or inhibiting its function in various pathological contexts. Overall, the investigation of Ptger2 as a recombinant protein holds the promise of enriching our understanding of its roles in health and disease, while also contributing to the identification of innovative therapeutic approaches targeting its signaling pathways.
